Gene Mutations Promising as a Test for Early Lung Cancer

Publication
Article
OncologyONCOLOGY Vol 9 No 5
Volume 9
Issue 5

Researchers at University of Texas Southwestern Medical Center at Dallas reported that alterations in the genes of a section of chromosome 3p may reveal the earliest stages of lung cancer.

Researchers at University of Texas Southwestern Medical Centerat Dallas reported that alterations in the genes of a sectionof chromosome 3p may reveal the earliest stages of lung cancer.

"Based on these findings, we may eventually be able to developa test that would predict who will develop lung cancer,"said Dr. Ali Gazdur, Professor of Pathology at UT Western. Thestudy was published in a recent issue of The Journal of theAmerican Medical Association.

Gazdur and his colleagues examined 24 human lung cancer specimensin the study. In the earliest stages of lung cancer, the UT Southwesternresearchers determined that genetic alterations or deletions haddeveloped in a region of chromosome 3p.

Another conclusion was reinforcement of the link between smokingand the development of such cancer. The study located gene alterationsthroughout the lung. "Our findings provide considerable supportfor the 'field cancerization' theory," Gazdur said. ""Thattheory suggests the entire upper respiratory tract is compromisedwhen exposed to carcinogens like those found in cigarette smoke.This raises the possibility that cancer may develop in multiplesections of the lung.

Finding defective genes may facilitate detection of early lungcancer, when treatment is most effective. In addition, if defectivegenes are found, but no malignant lesions can be identified, itmay allow physicians to better counsel the patient about his orher risk of developing lung cancer.

Gazdur's collaborators in the study included Dr. John Minna, directorof the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern,and other investigators at UT Southwestern.

Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.
Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
Thomas Marron, MD, PhD, presented a session on clinical data that established standards of care for stage II and III lung cancer treatment at CFS 2025.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
Related Content